Moreover, PARP‐1 inhibition has been reported to reduce the proliferation and promote radiation sensitization in CNE‐2 human NPC cells, which suggested that PARP may be an attractive target for the cancer therapy including NPC (Chen, Zhao, et al., 2015). This evidence concerns the gene PARP1 and nasopharyngeal carcinoma.